Reports from Virginia Commonwealth University Add New Data to Findings in Non-Alcoholic Steatohepatitis (Results From a New Efficacy and Safety Analysis of the Regenerate Trial of Obeticholic Acid for Treatment of Pre-cirrhotic Fibrosis Due To...).

Předmět:	NON-alcoholic fatty liver disease FATTY liver HEPATIC fibrosis FIBROSIS FARNESOID X receptor CLINICAL trials
Zdroj:	Hepatitis Weekly; 1/9/2024, p1285-1285, 1p
Abstrakt:	A recent study conducted by researchers at Virginia Commonwealth University has found that obeticholic acid (OCA) shows promise as a treatment for pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis (NASH). The study analyzed data from the phase III REGENERATE trial and found that OCA led to significant improvements in fibrosis and NASH resolution compared to a placebo. The study also found that OCA was generally well-tolerated with low rates of adverse events. These findings suggest that OCA may have a positive benefit:risk profile for patients with pre-cirrhotic liver fibrosis due to NASH. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu